.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Ovarian cancer (OC) remains a major clinical challenge because doctors often diagnose it at advanced stages. At this point, tumor heterogeneity and chemoresistance significantly impact survival rates. However, ovarian cancer organoids derived from ascites now offer a promising way to predict patient responses. These patient-derived organoids (PDOs) mimic the biological complexity of the parental tumor. Consequently, they provide a "living biobank" for precise drug testing.
Researchers recently achieved an 86.2% success rate in establishing these organoid models. Furthermore, whole-exome sequencing confirmed that the PDOs maintained the genomic features of the original cancer. The models accurately predicted how patients would respond to cisplatin and PARP inhibitors during their clinical treatment. This high level of fidelity makes them an ideal platform for personalized oncology.
One of the most exciting findings involves the oncolytic virus OH2. This modified herpes simplex virus 2 directly kills cancer cells, even in cisplatin-resistant cases. Additionally, combining OH2 with cisplatin significantly reduced the CD44+ cancer stem cell population. Since these stem cells often drive recurrence, this combination offers a novel strategy to overcome resistance. Therefore, using PDOs for individualized testing could drastically improve clinical outcomes for ovarian cancer patients.
Current research shows a high success rate of approximately 86.2%, allowing for reliable patient-specific modeling and drug sensitivity testing within a clinically relevant timeframe.
The OH2 virus acts as an oncolytic agent that directly kills cancer cells. Notably, it works synergistically with cisplatin to target and reduce the subpopulation of cancer stem cells that typically cause drug resistance.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship between the reader and the author. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Zhang X et al. Targeting cancer stem cells predicts response and reverses chemoresistance in ascites-derived ovarian cancer organoids. BMC Med. 2026 Feb 24. doi: 10.1186/s12916-026-04730-1. PMID: 41731502.
Nanki K et al. Patient-derived ovarian cancer organoids mimic parental tumor biology and predict drug responses. Nature Communications. 2020;11:4211.
Zhang B et al. Oncolytic herpes simplex virus 2 (OH2) for cancer therapy. Frontiers in Oncology. 2021;11:665555.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Study shows that ascites-derived organoids accurately predict cisplatin response and that OH2 virus combined with chemotherapy targets cancer stem cells....
6 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
